GPT Healthcare Limited

Regd. Office: GPT Centre, JC-25, Sector III, Salt Lake, Kolkata – 700 106, India CIN : L70101WB1989PLC047402
Phone : +91-33-4050-7000, Email : info@gptgroup.co.in , Visit us: www.gptgroup.co.in

GPTHEALTH/CS/SE/2026-27 **November 5, 2026**

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 **Scrip Code: 544131**	**National Stock Exchange of India Limited** Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 **Scrip Symbol: GPTHEALTH**
ISIN: INE486R01017	

Dear Sir/Madam

Sub: Submission of Investor Presentation on Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2026:

In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a copy of Investor Presentation on Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2026 for dissemination to general public and Investors.

Kindly take the aforesaid information on record and oblige.

Thanking You,

Yours sincerely,

For GPT Healthcare Limited

ANKUR SHARMA
Digitally signed by ANKUR SHARMA
Date: 2026.11.05 17:41:25 +05'30'

Ankur Sharma
Company Secretary and Compliance Officer
M. No A31833

Encl. As Above.

GPT HEALTHCARE LIMITED

Investor Presentation Q2 & H1FY27



Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **GPT Healthcare Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contractor binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guaranteeing of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Key Highlights of the Q2 & H1FY27

- ARPOB grew 7.1% YoY to ₹40721, reflecting improved realisations supported by a stronger clinical offering, a favourable speciality mix and enhanced operational efficiencies. Network occupancy in Q2FY27 has improved from 47.4% to 50.3% (59.8% excluding Raipur) indicating better utilisation of the hospital network.

- During H1 FY27, mature hospitals continued to demonstrate resilient operating performance, contributing ₹261.8 crore in revenue, ₹56.0 crore in EBITDA and ₹28.1 crore in PAT, with an EBITDA margin of approximately 21%.ILS Dum Dum remained the largest revenue contributor, reflecting its strong patient volumes and established clinical presence.

- ILS Raipur achieved NABH accreditation within its first year, performed its first TAVI procedure and liver transplant in Q2 FY27, and completed 11 renal transplants within a year.

- ILS Agartala Oncology program continues to gain strength with over 3200 radiation therapy procedures through its Linear Accelerator facility, and over 1000 PET scans in just over a year.

- ILS Salt Lake has crossed 850 robotic surgeries, while ILS Howrah, equipped with the MAKO robotic system, is nearing 100 robotic procedures.

- The upcoming 155-bed tertiary care hospital in Jamshedpur is progressing as planned and is expected to commence operations in March/April 2027.

- Building on its established presence in Eastern India, strong clinical capabilities and disciplined expansion strategy, the company is targeting long-term ROCE and ROE of approximately 25%, while evaluating additional greenfield expansion opportunities.

Company Overview

GPT Healthcare Limited is a fast-growing hospital platform in Eastern India, operating five, tertiary-care hospitals located within densely populated residential areas.

Designed around a proximity-based model, its hospitals offer the reassurance of advanced medical care almost at the doorstep—ensuring high accessibility for patients while enabling strong control over clinical quality, operating standards, and long-term returns on capital.

Led by Dr. Om Tantia, the company follows a disciplined, capital-efficient operating model with advanced capabilities across oncology, cardiology, renal transplants, and robotic surgeries.

With a clearly defined plan to scale to a 1,000-bed network by FY2027, supported by integrated diagnostics and a strong regional brand, GPT Healthcare is well positioned to capture rising healthcare demand, enhance profitability, and deliver sustained value to investors.



719
Beds- total capacity



122
Full time consultants



642
Visiting consultants



900+
Robot-enabled Surgeries



NABH & NABL accreditations




Optimally sized Hospitals



Financial Snapshot

Financial Snapshot for Q2 & H1FY27



Existing hospitals
- Salt lake
- Dum Dum
- Howrah
- Agartala
- Raipur

Upcoming Hospitals
- Jamshedpur

Other proposed Hospitals

Q2 FY27

Revenue from Operations

Rs 135.6 Cr

(Raipur – Rs 9.0 Cr, Mature – Rs 126.6 Cr
14.1% YoY

EBITDA & EBITDA Margin

Rs 29.8 Cr

(Overall – 21.5% Margin,
23.9% YoY)

PAT & PAT Margin

Rs 15.4 Cr

(11.1% Margin
45.2% YoY)

ARPOB

Rs 40,721

Occupancy Rate %

50.3%

Raipur – 16.5%, Mature – 59.8%

H1 FY27

Revenue from Operations

Rs 261.8 Cr

(Raipur – Rs 19.6 Cr, Mature – Rs 242.2 Cr
15.8% YoY)

EBITDA & EBITDA Margin

Rs 56.0 Cr

(Overall – 21.0% Margin,
30.3 % YoY)

PAT & PAT Margin

Rs 28.1 Cr

(10.5% Margin
53.9% YoY)

ARPOB

Rs.41,490


Occupancy Rate %

47.9%

Raipur – 17.0%, Mature – 56.7%


*planned hospital
ARPOB- Average Rate Per Occupied bed ; ALOS- Average length of stay

Hospital-wise performance for Q2 & H1 FY27











Year of commissioning	2000		2011		2013		2019		2025	
	Q2 FY27	H1FY27	Q2 FY27	H1FY27	Q2 FY27	H1FY27	Q2 FY27	H1FY27	Q2 FY27	H1FY27
Bed capacity (No of beds)	85		205		155		116		158	
Revenue (INR Cr)	22.2	44.0	39.7	74.8	45.1	84.8	19.7	38.5	9.0	19.6
Occupancy Rate (%)	68.4%	65.4%	53.7%	49.6%	73.3%	69.4%	46.4%	45.8%	16.5%	17.0%
ARPOB (INR)	41,480	43,284	39,154	40,254	43,125	43,086	39,672	39,556	37,347	39,885



Hospital Portfolio

ILS Salt Lake Hospital

85-bed tertiary surgical hospital with 17 ICUs and 3 OTs, scaled from an 8-bed facility.


Clinical focus on robotic gastro and bariatric surgeries, enabling higher case complexity.

Specialised care offerings including diabetic foot care and advanced gastroenterology


NBE-accredited Minimal Access Surgery department, serving as an FNB training centre



Bed Occupancy Rate (%)



ARPOB (INR per day)



ILS Agartala Hospital

205-bed ,corporate hospital with 66 ICUs, 8 OTs and 1 cath lab, offering large-scale critical care capacity


Clinical leadership in the state, with multiple first-in-Tripura procedures including leadless dual chamber implantation and complex vascular stenting

Only private hospital in Tripura accredited by both NABH and NABL, underscoring quality and compliance


Has evolved into a medical value travel hub, attracting international patients. Among the few hospitals in the region with end-to-end oncology care, supported by LINAC technology



Bed Occupancy Rate (%)



ARPOB (INR per day)



ILS Dum Dum Hospital

155-bed, six-storey tertiary facility with strong focus on multispecialty and critical care delivery


Licensed for renal transplants with upgraded gastroenterology services, forming the core specialty base

Known for renal and cardiac care, with respiratory ICU and cardiac surgery services to be launched shortly


Advanced diagnostic capabilities including MRI, CT, digital X-ray, and 3D imaging for interventional neurology



Bed Occupancy Rate (%)



ARPOB (INR per day)



ILS Howrah Hospital

116 Bed, Multi-specialty tertiary care hospital in Howrah, located near Railway Station, with no competing hospital within a 5-km radius


Launched robot-assisted orthopaedic surgery, including robotic knee replacements.

Emergency services upgraded, with capacity expanded from 2 to 10 beds, enhancing critical care readiness and patient throughput.


Achieved EBITDA breakeven within 8 months of inauguration, among the fastest breakeven timelines in India's tertiary care hospital sector.



Bed Occupancy Rate (%)



ARPOB (INR per day)



ILS Raipur Hospital

158 Bed ,Quaternary care hospital commencing its operations from May 2025, at Pachpedi Naka, serving a large catchment across Raipur, Bilaspur, Durg and Bhilai


The Renal transplant program is commenced and chemotherapy & oncology surgeries fully operational

Progressive expansion into advanced oncology care and license received for liver transplant services


High-end clinical infrastructure, including 3 Tesla MRI, cardiac catheterization lab, and dual-source CT scanner, enabling precision-led care



Bed Occupancy Rate (%)



ARPOB (INR per day)



Our cutting-edge investments



Robotic assisted GI Surgery



MAKO – Orthopedic robot for joint replacement



3 Tesla MRI and Cath Lab Facilities



Well- equipped ICU’s and NICU’s



Radiation and oncology



State-of-the-art Operation theatres

Technology-Enabled Healthcare Innovation

SPARSH – Healthcare at home for senior citizens

A home healthcare service for senior citizens, offering medical support and personalized care for an affordable annual fee of INR 500. The plan includes monthly doctor visits, routine checks, and discounts on OPD, IPD, diagnostics, and physiotherapy. It provides free sample collection, report delivery, complimentary ambulance (within 5 km), and priority admission

ILS-My Health app enhancing patient convenience

a user-friendly mobile application that enables seamless self-service appointment booking, real-time access to medical records, and instant hospital-related information without human intervention

HMIS enhancing efficiency and patient care

Hospital Management Information System to create a comprehensive digital framework for managing electronic medical records

Advancing healthcare through cutting edge technology

Installed cutting-edge robotic surgical technology in Salt Lake and Howrah Hospital with 750+ robotic surgeries successfully performed from the robot in Salt Lake.



Emerging Markets, Proposition & Path Ahead

Emerging Opportunities in Industry (1/2)

High – Multiple Growth expected

Attractive **20x–30x EBITDA** valuations amid strong growth in India's healthcare market.

Medical Tourism growth corridor

Eastern India is emerging as a **hub for international patients** from Bangladesh, Nepal, Bhutan with its market expected to reach **$13.42 billion by 2026**.

Policy-Backed

INR 99,858 crore healthcare outlay by govt., including Ayushman Bharat and NHM is accelerating demand for more quality-focused health care.

Untapped Rural Healthcare demand

Large gaps in healthcare access in remote regions create **scope for infrastructure development** and outreach programs.

Medical Devices- Scalable growth Market

Technology-enabled hospitals in Tier-2 and Tier-3 cities stand to capture outsized growth as India emerges **as a top-20 global healthcare market for medical devices**

Digital Health Scale- Up Potential

Growing **digital adoption** enables hospital apps to deliver telemedicine, AI diagnostics, and remote monitoring, **enhancing access and lowering costs.**

Emerging Opportunities in Industry (2/2)



Global Health-care demand

The global healthcare market is projected **to reach $ 665.37 billion by 2028**.



Work Force shortage

Persistent **shortages of doctors and nurses** are accelerating the shift toward organized healthcare platforms that can attract talent, standardize care, and scale efficiently



Less Supply & Affordability Gap

India's **~3 million bed shortfall,** combined with rising **disposable incomes,** supports a long-term expansion opportunity for scalable, affordable hospital networks



Government led healthcare infra- development

PM-ABHIM is driving **large-scale investment in healthcare infrastructure and critical care**, supporting long-term capacity expansion and demand growth across the sector



Relief on life saving Drugs

Government **duty exemptions on 36 life-saving drugs** improve affordability and create a demand tailwind for the healthcare sector



Structural Demand Upside


An **ageing demographic profile,** with median age projected at 38.3 by 2050, underpins sustained **demand growth for specialized, chronic, and tertiary hospital services**.

Key Investment Proposition



Eastern India Market Leadership	**Expand in Eastern India** by leveraging strong **regional brand equity** and capitalizing on **rising healthcare demand**.
Strategic Positioning	Leverage strategic locations in **dense residential area near transport hubs** to create easy patient access.
Optimized Price Value Mix	Calibrate pricing to deliver **high-quality, accessible care for middle-to-high income segments**, driving volume growth while protecting margins
High – Quality Payor Mix	Secure over 90% revenue from cash and insured patients, ensuring **minimal dependence on Govt schemes or Corporates**.
Capital- Efficient Execution	Deliver best-in-class execution with **industry-fastest break-even (8–10 months)** and **capex per bed at ₹7–8Mn**, well below industry norms and **net-debt free**.

Path Ahead



Unlocking Operating leverage

Target ≥70% bed occupancy across mature hospitals through disciplined capacity utilization, equipment optimization, and phased expansion

Next-Gen Care Delivery

Robotic surgery integrated as part of a technology-enabled care platform, complemented by the adoption of advanced medical innovations

Rapid Capacity Expansion

Scale to 1,000 beds within two years through strategic expansion in Tier I and Tier II Eastern India markets

Quality- Led Returns

Maintain long term ROE and ROCE ~ 25% alongside ongoing enhancements in care quality and patient

Balanced specialty mix

To have doctor-agnostic & broad specialty platform along with diversified case-mix helping in introducing new services as per the demand

Asset-Light Expansion

Rapid scale-up with low capital intensity through asset-light models that drive faster expansion with disciplined risk and minimal balance-sheet strain

Short- term Outlook



Strategic Expansion Outlook

- **Jamshedpur Hospital:** MoU signed for a **155-bed** facility with **INR 75 crore** investment, targeted commissioning by end-FY27.
- Planned entry into Tier II cities (Uttar Pradesh, Assam, Odisha) and select Tier I locations in Eastern India.
- **Land and building funded by developers;** operations run on fixed rental arrangements, enabling capital-efficient scaling and faster ROCE accretion

Operational & Clinical Capability Enhancement


- **Agartala**: Launched Comprehensive Cancer Care (PET scan + Linear Accelerator), making it the only integrated oncology unit in Tripura.
- **Howrah:** Commenced robotic knee replacement surgeries, expected to increase ARPOB and reduce ALOS.
- **Occupancy Upside:** Targeted ramp-up at Agartala and Howrah from ~55% to 70–75%, unlocking margin expansion.




Financial & Operational Highlights

Key financial metrics


Revenue from Operations (INR Cr)




EBITDA (INR Cr) & EBITDA Margin (%)




PAT (INR Cr) & PAT Margin (%)



ROE(%) and ROCE(%)




Net Debt to Equity (x times)




Key operational metrics


No of Beds & Occupancy Rate (%)




Average length of stay (days)




Average Revenue per Occupied Bed (INR)



Total Patient Volume




Hospital Revenue (INR Cr)




Revenue distribution of care services across hospitals


FY25



FY26



H1FY27



Internal Medicine & Diabetology
Nephrology with Renal transplants
GI Surgery
Critical Care
Pediatrics
Gastroenterology
Gynaecology and obstetrics
Cardiac Sciences
Orthopaedics and Joint Replacement
Neurosciences
Others
Oncology

Profit and Loss Highlights – Q2 & H1FY27

Particulars	Q2 FY27	Q2 FY26	Y-o-Y	Q1 FY27	Q-o-Q	H1FY27	H1FY26	Y-o-Y
Revenue from Operations	135.6	118.9		126.2		261.8	226.0	
Other Operating Income	2.9	1.3		2.0		5.0	2.9	
Total Revenue	**138.6**	**120.2**	**15.2%**	**128**	**8.1%**	**266.8**	**228.9**	**16.5%**
Cost of Material Consumed	25.9	22.2		24.1		50.1	42.9	
Employee Benefits Expenses	23.3	20.3		23.2		46.5	40.7	
Other Expenses	59.5	53.7		54.6		114.2	102.3	
EBITDA	**29.8**	**24.1**	**23.9%**	**26.2**	**13.8%**	**56.0**	**43.0**	**30.3%**
EBITDA Margin (%)	**21.5%**	**20.0%**		**20.4%**		**21.0%**	**18.8%**	
Depreciation	7.0	6.8		6.9		13.9	13.0	
EBIT	**22.8**	**17.2**	**32.2%**	**19.3**	**17.8%**	**42.1**	**30.0**	**40.4%**
EBIT Margin (%)	**16.4%**	**14.3%**		**15.1%**		**15.8%**	**13.1%**	
Finance Cost	2.1	2.2		2.2		4.3	3.8	
Profit before Tax	**20.7**	**15.1**	**37.2%**	**17.2**	**20.5%**	**37.8**	**26.2**	**44.5%**
Profit before Tax(%)	**14.9%**	**12.5%**		**13.4%**		**14.2%**	**11.4%**	
Tax	5.3	4.5		4.4		9.7	7.9	
Profit After Tax	**15.4**	**10.6**	**45.2%**	**12.7**	**21.0%**	**28.1**	**18.3**	**53.9%**
PAT Margin (%)	**11.1%**	**8.8%**		**9.9%**		**10.5%**	**8.0%**	
EPS (As per Profit after Tax) Basic	1.9	1.3		1.6		3.4	2.2	

Figures marked * are not annualised

Consolidated Balance sheet

Assets (Rs Cr)	H1FY27	FY26
Property, plant and equipment	264.8	265.4
Capital WIP	8.1	0.7
Other Non-current Assets	103.8	109.3
Non- Current Assets	**376.6**	**375.5**
Inventories	11.6	10.6
Debtors	31.6	20.3
Cash Equivalents & Bank	1.2	4.5
Loans	0.3	1.2
Investments	45.5	42.9
Other Current Assets	14.1	10.2
Current Assets	103.4	89.3
Total Assets	**480.1**	**464.7**
Liabilities (Rs Cr)	**H1FY27**	**FY26**
Share Capital	82.1	82.1
Other Equity	203.1	187.4
Total Equity	285.2	269.4
Borrowings	2.7	7.2
Lease Liabilities	69.5	69.5
Other Non- current Liabilities	40.3	39.2
Non- Current Liabilities	112.4	115.8
Borrowings	12.2	8.9
Trade Payables	43.7	41.9
Provisions	0.3	0.2
Other Financial Liabilities	12.3	16.6
Other Current Liabilities	13.8	11.8
Current Liabilities	82.4	79.5
Total Liabilities	**194.9**	**195.3**
Total Equity & Liabilities	**480.1**	**464.7**

Consolidated Cashflow

Cash Flow Statement (Rs. Crs.)	H1FY27	H1FY26
Profit before Tax	37.8	26.2
Adjustment for Non-Operating Items	0.1	0.1
Operating Profit before Working Capital Changes	**52.6**	**40.7**
Changes in Working Capital	14.7	-0.8
Cash Generated from Operations	**37.9**	**41.4**
Less: Direct Taxes paid	3.7	7.8
Net Cash from Operating Activities	**34.2**	**33.6**
Cash Flow from Investing Activities	-16.5	-22.8
Cash Flow from Financing Activities	-21.0	-11.1
Net increase/ (decrease) in Cash & Cash equivalent	**-3.2**	**-0.2**
Add: Cash and cash equivalents as at 1st April	4.1	1.7
Cash and cash equivalents as at 31st March	**0.9**	**1.5**

Historical Profit and Loss Statement

Particulars	FY24	FY25	FY26
Revenue from Operations	400.2	407.1	472.5
Other Operating Income	5.3	8.5	6.0
Total Revenue	**405.7**	**415.6**	**478.5**
Cost of Material Consumed	83.0	78.8	89.8
Employee Benefits Expenses	68.9	73.0	84.4
Other Expenses	160.5	171.9	214.2
EBITDA	**93.1**	**91.8**	**90.1**
EBITDA Margin (%)	**23.0%**	**22.1%**	**18.8%**
Depreciation	18.0	19.0	27.1
EBIT	**75.1**	**72.8**	**63.1**
EBIT Margin (%)	**18.5%**	**17.5%**	**13.2%**
Finance Cost	7.1	3.5	8.2
Profit before Tax	**68.0**	**69.3**	**54.8**
Profit before Tax(%)	**16.8%**	**16.7%**	**11.5%**
Tax	20.3	19.4	12.6
Profit After Tax	**47.8**	**49.9**	**42.2**
PAT Margin (%)	**11.8%**	**12.0%**	**8.8%**
EPS (As per Profit after Tax) Basic	6.0	6.1	5.2

Historical Balance sheet

Assets (Rs Cr)	FY24	FY25	FY26
Property, plant and equipment	201.1	202.6	256.4
Capital WIP	6.4	46.3	0.7
Other Non- Current assets	57.9	56.5	109.3
Non- Current Assets	**265.4**	**305.4**	**375.5**
Inventories	8.2	8.9	10.6
Debtors	24.3	19.7	20.3
Cash Equivalents	9.1	4.3	4.1
Loans	11.2	0.2	1.2
Investments	11.2	32.0	42.9
Other Current Assets	16.2	13.8	10.2
Current Assets	80.1	78.8	89.3
Total Assets	**345.5**	**384.3**	**464.7**
Liabilities (Rs Cr)	**FY24**	**FY25**	**FY26**
Share Capital	82.1	82.1	82.1
Other Equity	136.4	165.8	187.4
Total Equity	**218.5**	**247.9**	**269.4**
Borrowings	3.6	5.5	7.2
Lease Liabilities	15.3	17.2	69.5
Other Non- current Liabilities	30.9	39.5	39.2
Non- Current Liabilities	**49.8**	**62.2**	**115.8**
Borrowings	8.8	7.8	8.9
Trade Payables	37.4	34.7	41.9
Provisions	1.2	0.6	0.2
Other Financial Liabilities	20.1	20.2	16.6
Other Current Liabilities	9.7	10.9	11.8
Current Liabilities	**77.2**	**74.2**	**79.5**
Total Liabilities	**127.0**	**136.4**	**195.3**
Total Equity & Liabilities	**345.5**	**384.3**	**464.7**

Historical Cash Flow Statement

Cash Flow Statement (Rs. Crs.)	FY24	FY25	FY26
Profit before Tax	68.0	69.3	54.8
Adjustment for Non-Operating Items	21.9	18.8	33.9
Operating Profit before Working Capital Changes	**90.0**	**88.1**	**88.7**
Changes in Working Capital	-6.2	-3.6	-5.5
Cash Generated from Operations	**83.8**	**84.5**	**94.2**
Less: Direct Taxes paid	-15.0	-17.1	-13.0
Net Cash from Operating Activities	**68.8**	**67.4**	**81.1**
Cash Flow from Investing Activities	-25.2	-32.6	-47.2
Cash Flow from Financing Activities	-48.5	-34.8	-31.4
Net increase/ (decrease) in Cash & Cash equivalent	**-4.9**	**-0.03**	**2.5**
Add: Cash and cash equivalents as at 1st April	6.6	1.7	1.7
Cash and cash equivalents as at 31st March	**1.7**	**1.7**	**4.1**

Professional and Experienced Leadership –Board of Directors



Dr. Om Tantia
Chairman & Managing Director

- Founding member of ILS Hospitals
- More than 40+ years of experience as a medical practitioner
- Recognized as a surgeon of excellence by Surgical Review Corporation, USA
- Fellow Member of the Association of Surgeons of India in general surgery
- Served as President of Association of the Minimal Access Surgeons of India

M C



Shree Gopal Tantia
Vice Chairman

- More than 40 years of experience in administrative and corporate governance roles



Anurag Tantia
Executive Director

- 12+ years of experience in healthcare management and looks after the day today operations of the Company
- Holds Bachelor of Science in Management with honors from University of Illinois

M M



Dr. Aruna Tantia
Non - Executive Director

- Senior consultant (gynecology and obstetrics) in ILS Hospitals
- 36+ years of experience as a medical practitioner
- Holds Bachelor of Medicine and Bachelor of Surgery from Ravindra Nath Tagore Medical College, Udaipur, University of Rajasthan and Master of Surgery in Obstetrics and Gynaecology from Bhupendra Narayan Mandal University, Bihar
- Fellow of The Association of Minimal Access Surgeons of India- FMAS

M



Dr. Ghanshyam Goyal
Non - Executive Director

- HOD of Diabetology at Salt Lake hospital since the year 2000
- Experience in general medicine and diabetology
- Holds Bachelor of Medicine, Bachelor of Surgery and Doctor of Medicine in general medicine from S.M.S. Medical College, University of Rajasthan



Kashi Prasad Khandelwal
Non-Executive Independent Director

- More than 4 decades of experience as a Chartered Accountant & expertise in Audit, Accounting, Direct and Indirect Tax, Corporate law matters.

M C



Dr. Tapti Sen
Independent Director

- Experience of almost 35 years as a medical practitioner
- Bachelor of Medicine, Bachelor of Surgery and Master of Surgery from University of Nagpur
- Serves as the Secretary of Kolkata Breast Health and Welfare Association

M M M



Hari Modi
Independent Director

- Graduated from the University of Calcutta and has passed the final examination of the Institute of Cost and Works Accountant of India

C M



Deepak Pramanik
Independent Director

- 30+ years of experience in management consultancy, human resources and finance
- Bachelor degree in Technology in Mechanical Engineering from IIT, Madras and a Post Graduate Diploma in Management from IIM, Calcutta

C



Amrendra Prasad Verma
Independent Director

- Experience in credit, finance and banking sectors
- Served as the MD and CEO of SBI Capital Markets Ltd and as a Deputy MD and Group Executive (Mid Corporate)band Chief Credit and Risk Officer of the State Bank of India

M

M Member M Chairman Stakeholders Relationship Committee CSR Committee Executive Committee Audit Committee Nomination & Remuneration Committee

Awards & Accreditations



Great place to work Award



Leading chain of multispecialty award



Best Health care brand



The Eastern India Best Employer Brand Awards



NABH Nursing Excellence Certification



The Happening awards Bengal Brilliance




Eastern India Leadership Awards



Quality Brand of India Award


Stock Information

Share Price Movement



Stock Price Chart as on 30th Sept-2026

Shareholding Pattern (Sept'26)



Stock Data (As on 30th Sept, 2026)	
BSE/NSE Code	544131 | GPTHEALTH
CMP (Rs)	150.85
Market Cap (Rs Cr)	1,237.80
Shares O/s (Cr)	8.21
Face Value (Rs)	10
Average Trading Volume ('000)	175

Source: NSE, BSE

COMPANY :

GPT HEALTHCARE LIMITED
CIN : L70101WB1989PLC047402
www.ilshospitals.com

INVESTOR RELATIONS ADVISORS :

Cygnus Partners Private Limited

Ms. Pooja Swami
Pooja.swami@cygnuspartners.in

Ms. Mamta Nehra
Mamta.nehra@cygnuspartners.in

THANK YOU

